^
    Back
    Association details:
    Biomarker:SMYD3 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Transl Oncol
    Title:

    SMYD3 confers cisplatin chemoresistance of NSCLC cells in an ANKHD1-dependent manner

    Published date:
    03/24/2021
    Excerpt:
    Expression pattern of SMYD3 was determined in NSCLC tissues using qRT-PCR, which also validated its correlation with NSCLC clinicopathological stages....Highly expressed SMYD3 was observed in NSCLC tissues or cells, acted as a sensitive indicator for NSCLC, correlated with higher TNM stages or resistant to DDP treatment, and shorter overall survival.
    DOI:
    10.1016/j.tranon.2021.101075